Lazard Asset Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$268K Sell
29,757
-20,880
-41% -$330K ﹤0.01% 1542
2025
Q4
$924K Buy
50,637
+16,028
+46% +$270K ﹤0.01% 1180
2025
Q3
$507K Buy
34,609
+513
+2% +$8.79K ﹤0.01% 1346
2025
Q2
$619K Sell
34,096
-385,571
-92% -$7.86M ﹤0.01% 1442
2025
Q1
$8.32M Buy
419,667
+71,068
+20% +$1.23M 0.01% 532
2024
Q4
$5.98M Buy
348,599
+96,689
+38% +$1.82M 0.01% 591
2024
Q3
$5.03M Buy
251,910
+48,802
+24% +$759K 0.01% 629
2024
Q2
$2.27M Buy
203,108
+92,299
+83% +$774K ﹤0.01% 838
2024
Q1
$730K Buy
110,809
+5,731
+5% +$31.3K ﹤0.01% 987
2023
Q4
$474K Buy
105,078
+1,327
+1% +$4.91K ﹤0.01% 1126
2023
Q3
$370K Buy
103,751
+18,295
+21% +$70.4K ﹤0.01% 1221
2023
Q2
$314K Buy
85,456
+7,429
+10% +$27.5K ﹤0.01% 1227
2023
Q1
$258K Hold
78,027
﹤0.01% 1252
2022
Q4
$302K Hold
78,027
﹤0.01% 1215
2022
Q3
$189K Hold
78,027
﹤0.01% 1279
2022
Q2
$154K Buy
78,027
+31,151
+66% +$61.3K ﹤0.01% 1355
2022
Q1
$85K Buy
46,876
+7,309
+18% +$11.4K ﹤0.01% 1471
2021
Q4
$55K Buy
+39,567
New +$52K ﹤0.01% 1692

Other funds holding ADMA

Lazard Asset Management's ADMA Position: Q1 2026 in Review

Lazard Asset Management reduced its ADMA Biologics (ADMA) stake by 41% in Q1 2026, selling an estimated $330K and leaving 29,757 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.

Lazard Asset Management first reported a position in ADMA in Q4 2021 and has held it in 18 quarters since. The position peaked at $8.32M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Lazard Asset Management held 29,757 shares of ADMA Biologics worth $268K as of Q1 2026.
  • Lazard Asset Management sold 20,880 ADMA Biologics shares in Q1 2026, an estimated $330K.
  • ADMA Biologics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1542 holding.
  • Lazard Asset Management first reported a position in ADMA Biologics in Q4 2021 and has held it in 18 quarters since.
  • Lazard Asset Management's ADMA Biologics position peaked at $8.32M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.